Product image of Metohexal Retard (Metoprolol Succinate) supplied by GNH India

Metohexal Retard

Active Ingredient:
Metoprolol Succinate
Origin:
EU

Metohexal Retard (Metoprolol Succinate)

Metoprolol succinate, the active ingredient in Metohexal Retard, is a beta blocker presented as an extended‑release tablet for oral use. It treats hypertension, angina pectoris, chronic heart failure and post‑myocardial infarction management in adults.

GNH India supplies Metohexal Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets and providing reliable logistics for global distribution.

Manufacturer / TM Owner

Hexal Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprolol succinate is used to manage cardiovascular conditions that involve elevated blood pressure or cardiac workload.

  • Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
  • Chronic heart failure: improves survival, reduces hospitalizations, and enhances functional capacity.
  • Post‑myocardial infarction: lowers the risk of recurrent events and mortality after a heart attack.

How It Works

  • Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate, myocardial contractility, and renin release. This leads to decreased cardiac output and lower arterial pressure, helping to control hypertension, reduce myocardial oxygen consumption, and improve outcomes in heart failure and post‑infarction patients.

Side Effects

Metoprolol succinate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Fatigue: feeling unusually tired or weak.
  • Dizziness: light‑headedness, especially when standing quickly.
  • Headache: mild to moderate pain in the head.
  • Bradycardia: slower than normal heart rate.
  • Cold extremities: reduced blood flow to hands and feet.
  • Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects

  • Severe bradycardia or heart block requiring medical attention.
  • Marked hypotension leading to fainting or shock.
  • Bronchospasm in patients with asthma or COPD.
  • Depression or mood changes.
  • Allergic reactions such as rash, itching, or swelling.
  • Worsening heart failure symptoms.

Precautions & Warnings

Before initiating therapy, consider the following safety measures.

  • Monitor blood pressure and heart rate regularly: ensure values remain within therapeutic targets.
  • Use caution in patients with asthma or chronic obstructive pulmonary disease: β1‑selectivity may not fully prevent bronchoconstriction.
  • Adjust dose in renal or hepatic impairment: reduced clearance can increase drug exposure.
  • Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
  • Contraindicated in second‑ or third‑degree atrioventricular block without a pacemaker.
  • Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Metoprolol succinate can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

  • Concomitant use with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause severe bradycardia or AV block.
  • Co‑administration with clonidine abrupt withdrawal: can precipitate hypertensive crisis.
  • MAO inhibitors (phenelzine, tranylcypromine): risk of hypertensive episodes.
  • Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.
  • NSAIDs (ibuprofen, naproxen): can diminish antihypertensive effect.

Moderate Interactions (Monitor Closely)

  • CYP2D6 inhibitors (fluoxetine, paroxetine): increase metoprolol plasma levels.
  • Diuretics (hydrochlorothiazide, furosemide): may enhance hypotensive response.
  • Antiplatelet agents (aspirin, clopidogrel): potential for increased bleeding risk.

Frequently Asked Questions

Metohexal Retard contains metoprolol succinate, a beta‑blocker indicated for hypertension, angina pectoris, chronic heart failure, and post‑myocardial infarction management. It helps lower blood pressure, reduce chest pain, improve heart‑failure outcomes, and decrease the risk of recurrent cardiac events after a heart attack.

Metoprolol succinate selectively blocks β1‑adrenergic receptors in cardiac tissue. By inhibiting these receptors, it reduces heart rate, myocardial contractility, and renin release, which together lower cardiac output and arterial pressure, thereby easing the workload on the heart.

The appropriate dose of Metohexal Retard is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metohexal Retard delivers metoprolol succinate in an extended‑release formulation, offering once‑daily dosing and stable plasma concentrations. Compared with immediate‑release beta blockers, it may provide smoother blood pressure control and better adherence, while sharing the same class‑related efficacy and safety profile.

Metohexal Retard tablets should be stored below 25 °C in their original container, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources, and keep out of reach of children.

Metohexal Retard is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole; it must not be split, crushed, or chewed to maintain the extended‑release properties.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and worsening heart‑failure symptoms. Patients should seek immediate medical attention if they experience fainting, severe dizziness, shortness of breath, or swelling of the face or throat.

Metohexal Retard is contraindicated in individuals with second‑ or third‑degree atrioventricular block without a pacemaker, severe sinus bradycardia, overt heart failure decompensation, or known hypersensitivity to metoprolol or any tablet excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT